Literature DB >> 29208775

CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity.

Crystal L Mackall1,2,3, David B Miklos1,3.   

Abstract

<b/> Central nervous system (CNS) toxicity associated with chimeric antigen receptor-based therapeutics has emerged as a significant cause of morbidity and mortality, and insights into the pathophysiology of this syndrome have been lacking. A new study provides evidence that cytokine-induced CNS endothelial cell activation leading to disruption of the blood-brain barrier plays an early and critical role in this phenomenon. These insights provide new opportunities for targeted therapeutic interventions to modulate endothelial cell activation. Cancer Discov; 7(12); 1371-3. ©2017 AACRSee related article by Gust et al., p. 1404. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 29208775     DOI: 10.1158/2159-8290.CD-17-1084

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  22 in total

Review 1.  Cellular therapy: Immune-related complications.

Authors:  Joseph H Oved; David M Barrett; David T Teachey
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

2.  Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques.

Authors:  Anandani Nellan; Cynthia M Lester McCully; Rafael Cruz Garcia; Nalini Jayaprakash; Brigitte C Widemann; Daniel W Lee; Katherine E Warren
Journal:  Blood       Date:  2018-06-28       Impact factor: 22.113

Review 3.  Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions.

Authors:  Prarthana J Dalal; Nikita P Patel; Matthew J Feinstein; Nausheen Akhter
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.

Authors:  Nirali N Shah; Steven L Highfill; Haneen Shalabi; Bonnie Yates; Jianjian Jin; Pamela L Wolters; Amanda Ombrello; Seth M Steinberg; Staci Martin; Cindy Delbrook; Leah Hoffman; Lauren Little; Anusha Ponduri; Haiying Qin; Haris Qureshi; Alina Dulau-Florea; Dalia Salem; Hao-Wei Wang; Constance Yuan; Maryalice Stetler-Stevenson; Sandhya Panch; Minh Tran; Crystal L Mackall; David F Stroncek; Terry J Fry
Journal:  J Clin Oncol       Date:  2020-04-14       Impact factor: 44.544

Review 5.  Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.

Authors:  Chelsea Kotch; David Barrett; David T Teachey
Journal:  Expert Rev Clin Immunol       Date:  2019-06-20       Impact factor: 4.473

Review 6.  Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.

Authors:  Allison Barz Leahy; Caitlin W Elgarten; Stephan A Grupp; Shannon L Maude; David T Teachey
Journal:  Expert Rev Anticancer Ther       Date:  2018-10       Impact factor: 3.627

7.  Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes.

Authors:  Liqing Kang; Xiaowen Tang; Jian Zhang; Minghao Li; Nan Xu; Wei Qi; Jingwen Tan; Xiaoyan Lou; Zhou Yu; Juanjuan Sun; Zhenkun Wang; Haiping Dai; Jia Chen; Guoqing Lin; Depei Wu; Lei Yu
Journal:  Exp Hematol Oncol       Date:  2020-06-08

8.  Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation.

Authors:  Yunshuo Chen; Ranran Li; Siqi Shang; Xuejiao Yang; Lei Li; Wenbo Wang; Yueying Wang
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

Review 9.  Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.

Authors:  Zhenguang Wang; Weidong Han
Journal:  Biomark Res       Date:  2018-01-22

10.  A conformation-specific ON-switch for controlling CAR T cells with an orally available drug.

Authors:  Charlotte U Zajc; Markus Dobersberger; Irene Schaffner; Georg Mlynek; Dominic Pühringer; Benjamin Salzer; Kristina Djinović-Carugo; Peter Steinberger; Annika De Sousa Linhares; Nicole J Yang; Christian Obinger; Wolfgang Holter; Michael W Traxlmayr; Manfred Lehner
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-17       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.